



Press Release

## **Cipla announces the next steps in its relationship with Serum Institute - an exclusive distribution agreement for flu vaccine 'Nasovac-S' for India**

**India, Mumbai, May 27, 2015:** Cipla Limited, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, today announced that it has signed an agreement with Serum Institute of India Ltd. (SII) – a global leader in the production of vaccines – to exclusively market flu vaccine Nasovac-S in India. Under this agreement, SII will develop and manufacture the vaccine, and Cipla will exclusively market it in India. The vaccine will be manufactured in Serum's world class production facilities approved by the WHO.

Commenting on the agreement, Mr. Subhanu Saxena, MD & Global CEO, Cipla Limited said: "We are extremely delighted to have entered into a strategic partnership with SII in India. This collaboration is aligned with our commitment to access to affordable healthcare. This partnership is a significant step towards making preventative healthcare accessible to a large number of Indians through Cipla's strong countrywide salesforce."

Having initiated the approval process with the European Medicines Authority for marketing the products developed and manufactured by SII, Cipla is now forging ahead looking at other markets where the company has a strong presence.

Influenza occurs globally with an annual attack rate estimated at 5%–10% in adults and 20%–30% in children. Worldwide, these annual epidemics are estimated to result in about 3 to 5 million cases of severe illness, and about 250 000 to 500 000 deaths. The advantage of Nasovac-S vaccine is that it is administered through the nasal route and is therefore painless. It increases indirect protection through herd immunity and protects against drifted viruses.

### **About Cipla Limited**

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Our portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.

Cipla's research and development focuses on developing innovative products and drug delivery systems and has given India and the world many 'firsts' for instance Triomune. In a tightly regulated environment, the company's manufacturing facilities have approvals from all the main regulators including USFDA, UKMHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one universal standard both domestically and internationally.

### **About Serum Institute of India Limited (SII)**

Serum Institute of India Limited is the world's second largest vaccine manufacturer in number of doses manufactured and supplied to more than 140 countries. The vaccines include Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps, Rubella, Meningitis A, Influenza and Polio vaccines. One of every two children born in the world receive a vaccine manufactured by Serum Institute.

#### **Media Contacts:**

##### **Corporate Communications**

Charlotte Chunawala

Mobile: +91 7506257377

E Mail: [charlotte.chunawala@cipla.com](mailto:charlotte.chunawala@cipla.com);

Pallavi Golar

Mobile: +91 9833641788

E Mail: [pallavi.golar@cipla.com](mailto:pallavi.golar@cipla.com)